949-69-9

Basic information

• Product Name: 1-benzyl-4-piperidone oxime
• Synonyms: 1-benzyl-4-piperidone oxime;1-Benzyl-piperidin-4-one oxime;1-Benzylpiperidine-4-oneoxime;N-[1-(phenylmethyl)piperidin-4-ylidene]hydroxylamine;1-benzyl-4-piperidon;4-Piperidinone,1-(phenylMethyl)-, oxiMe;N-benzyl-4-(N-hydroxyimino)piperidine
• CAS NO: 949-69-9
• Molecular Formula: C₁₂H₁₆N₂O
• Molecular Weight: 204.26824
• EINECS: 213-443-1
• Product Categories: Piperidine
• Mol File: 949-69-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 338.5°C at 760 mmHg
• Flash Point: 158.5°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 3.82E-05mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-benzyl-4-piperidone oxime(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-4-piperidone oxime(949-69-9)
• EPA Substance Registry System: 1-benzyl-4-piperidone oxime(949-69-9)

Safety Data

• Hazardous Substances Data: 949-69-9(Hazardous Substances Data)

Usage

General Description

1-benzyl-4-piperidone oxime is a chemical compound with the molecular formula C14H17NO. It is derived from piperidone, a heterocyclic compound, and is commonly used as a reagent in organic synthesis. 1-benzyl-4-piperidone oxime is mainly utilized in the preparation of other chemical compounds and in various chemical reactions, including the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals. It is also known for its potential pharmacological properties and has been studied for its potential use in the treatment of various medical conditions. However, it is important to handle this chemical with caution, as it may have toxic properties and should be used in accordance with proper safety protocols.

InChI:InChI=1/C12H16N2O/c15-13-12-6-8-14(9-7-12)10-11-4-2-1-3-5-11/h1-5,15H,6-10H2

Upstream product

• 20821-52-7 1-benzyl-4-piperidone hydrochloride 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 55186-89-5 1-benzyl-1,4-diazepan-5-one 
• 272442-27-0 5-benzyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine 
• 795310-37-1 4-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)piperidine 
• 795310-77-9 1-benzyl-4-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)piperidine 
• 312924-69-9 N-(1-benzylpiperidin-4-yl)isobutyramide 
• 139062-93-4 N-(1-benzylpiperidin-4-yl)propionamide 
• 34376-54-0 [1,4]diazepan-5-one 
• 1446219-98-2 C₂₆H₂₇N₃O₂ 

Relevant articles and documents

ANTIVIRAL OXIME PHOSPHORAMIDE COMPOUNDS

Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

SUBSTITUTED 1-ARYLETHYL-4-ACYLAMINOPIPERIDINE DERIVATIVES AS OPIOID/ALPHA-ADRENORECEPTOR MODULATORS AND METHOD OF THEIR PREPARATION

The invention provides compounds that bind with high affinities to the μ-, δ- and κ- opioid receptors and α2 - adrenoreceptor. In addition to providing these compounds with novel pharmacological binding properties, the invention also describes detailed novel methods for the preparation of representative compounds and a scheme for the synthesis of related compounds that bind to the opioid receptors and/or α2 - adrenoreceptor.

Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2

Mutations in leucine-rich repeat kinase-2 (LRRK2) are the most common genetic cause of Parkinson's disease (PD). The most frequent kinase-enhancing mutation is the G2019S residing in the kinase activation domain. This opens up a promising therapeutic avenue for drug discovery targeting the kinase activity of LRRK2 in PD. Several LRRK2 inhibitors have been reported to date. Here, we report a selective, brain penetrant LRRK2 inhibitor and demonstrate by a competition pulldown assay in vivo target engagement in mice.